Enfusion (ENFN) Stock Price, News & Analysis

Company Overview

Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers Accounting/General Ledger System, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion Analytics System, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion, Inc. was founded in 1997 and is headquartered in Chicago, Illinois.

Key Stats

• Today's Range: $10.22 to $10.74
• 50-Day Range: $8.72 to $11.03
• 52-Week Range: $7.52 to $11.38
• Volume: 935,391 shs
• Average Volume: 390,961 shs
• Market Capitalization: $1.37 billion
• P/E Ratio: 265.82
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Reduce

Enfusion Stock Analysis - MarketRank™

Enfusion scored higher than 57% of companies evaluated by MarketBeat, and ranked 315th out of 652 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.9 / 5
• Analyst Rating: Reduce

Consensus Rating

Enfusion has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on 2 buy ratings, no hold ratings, and 3 sell ratings.

Amount of Analyst Coverage

Enfusion has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 150.00%

Earnings Growth

Earnings for Enfusion are expected to grow by 150.00% in the coming year, from $0.06 to $0.15 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Enfusion is 265.82, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 120.38.

Price to Earnings Ratio vs. Sector

The P/E ratio of Enfusion is 265.82, which means that it is trading at a more expensive P/E ratio than the Computer and Technology sector average P/E ratio of about 244.61.

Price to Earnings Growth Ratio

Enfusion has a PEG Ratio of 3.98. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Enfusion has a P/B Ratio of 17.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.67% of the float of Enfusion has been sold short.

Short Interest Ratio / Days to Cover

Enfusion has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Enfusion has recently decreased by 19.57%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Enfusion does not currently pay a dividend.

Dividend Growth

Enfusion does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.67% of the float of Enfusion has been sold short.

Short Interest Ratio / Days to Cover

Enfusion has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Enfusion has recently decreased by 19.57%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 0.92

News Sentiment

Enfusion has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Computer and Technology companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Enfusion this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for ENFN on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Enfusion to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Enfusion insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $224,696.00 in company stock.

Percentage Held by Insiders

36.44% of the stock of Enfusion is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

81.05% of the stock of Enfusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ENFN Stock Analysis - Frequently Asked Questions

How have ENFN shares performed this year?

Enfusion's stock was trading at $9.70 on January 1st, 2024. Since then, ENFN stock has increased by 9.6% and is now trading at $10.63.
View the best growth stocks for 2024 here.

How were Enfusion's earnings last quarter?

Enfusion, Inc. (NYSE:ENFN) posted its quarterly earnings results on Thursday, May, 9th. The company reported ($0.01) earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by $0.05. The company earned $48.05 million during the quarter, compared to analysts' expectations of $47.67 million. Enfusion had a trailing twelve-month return on equity of 6.67% and a net margin of 1.70%.

When did Enfusion IPO?

Enfusion (ENFN) raised $300 million in an initial public offering (IPO) on Thursday, October 21st 2021. The company issued 18,750,000 shares at $15.00-$17.00 per share.

Who are Enfusion's major shareholders?

Top institutional investors of Enfusion include Brown Capital Management LLC (5.61%), Janus Henderson Group PLC (1.28%), New York State Common Retirement Fund (1.21%) and Geode Capital Management LLC (0.80%). Insiders that own company stock include Neal Pawar, Oleg Movchan, Bronwen Bastone, Dan Groman, Matthew Campobasso, Deirdre Somers, Valeria Gutowski, Tarek Hammoud and Stephen Malherbe.
View institutional ownership trends.

How do I buy shares of Enfusion?

Shares of ENFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Enfusion own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Enfusion investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 5/09/2024
• Today: 12/20/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Computer and Technology
• Industry: Prepackaged software
• Sub-Industry: N/A
• Current Symbol: NYSE:ENFN
• CUSIP: N/A
• CIK: 1868912
• Web: www.enfusion.com
• Phone: 312-253-9800
• Fax: N/A
• Employees: 1,102
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.00
• High Stock Price Target: $13.00
• Low Stock Price Target: $8.00
• Potential Upside/Downside: -5.9%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.04
• Trailing P/E Ratio: 265.82
• Forward P/E Ratio: 177.17
• P/E Growth: 3.98
• Net Income: $6.03 million
• Net Margins: 1.70%
• Pretax Margin: 3.64%
• Return on Equity: 6.67%
• Return on Assets: 4.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.62
• Quick Ratio: 3.62

Sales & Book Value

• Annual Sales: $195.16 million
• Price / Sales: 7.00
• Cash Flow: $0.14 per share
• Price / Cash Flow: 73.89
• Book Value: $0.61 per share
• Price / Book: 17.43

Miscellaneous

• Outstanding Shares: 128,571,000
• Free Float: 81,720,000
• Market Cap: $1.37 billion
• Optionable: Optionable
• Beta: 0.97